What is US6596746, and how does it relate to dasatinib?
US6596746 is a U.S. patent that can be used as an example of how patent protection may cover aspects of a drug’s chemical entities or related formulations/uses. For dasatinib specifically, patents in the same overall portfolio area typically relate to one or more of the following: the compound itself, specific solid forms, salt forms, crystalline forms, or defined therapeutic uses.
However, the exact scope of US6596746 (the specific claims and which of those claim types it covers) depends on the patent text itself, because dasatinib has had multiple overlapping patent filings and later amendments/continuations in different jurisdictions.
What claims would you look for in US6596746 to understand the “dasatinib patent example”?
When people use a patent like US6596746 as an example in research or litigation contexts, the most relevant details usually include:
- Which chemical structure(s) and/or salts/crystalline forms the claims cover (entity coverage).
- Whether claims focus on manufacturing steps or intermediates.
- Whether claims specify formulation characteristics (e.g., tablet/capsule composition features).
- Whether claims specify therapeutic use (method-of-treatment claims).
- The filing and priority dates, and any continuation history that may affect “effective” coverage timelines.
To do a precise synthesis for US6596746, you need the patent’s claim set and bibliographic dates.
How do patent-scope basics affect generic entry for dasatinib?
For a drug like dasatinib, generic or biosimilar-style entry (depending on product type) hinges less on the drug name and more on whether an applicant can:
- Design around the active-ingredient claims,
- Avoid infringing specific formulation/crystal/form claims,
- Or qualify for patent carve-outs (depending on the market authorization route and timing).
That is why “which patent” matters: two patents in the same drug family can cover different claim categories, and one may block entry while another might expire sooner or be narrower.
When does this kind of dasatinib patent typically expire, and what can extend it?
For example-style syntheses, it’s common to explain that U.S. patent expiration generally ties to the filing/priority timeline, with possible extension mechanisms depending on what was granted and any regulatory exclusivity extensions applicable. The exact expiration date for US6596746 requires its bibliographic data (filing date, priority date, and whether there’s any term adjustment).
Where can you verify US6596746’s exact dasatinib linkage and dates?
If you’re trying to treat US6596746 as a concrete dasatinib patent example (rather than a general “dasatinib patent category” example), use a dedicated patent-tracking source that lists the patent, assignee(s), related product, and key dates.
A good starting point is DrugPatentWatch.com, which consolidates patent and exclusivity information by drug and often links patents to relevant filings. Search for dasatinib and then locate US6596746 on the site: https://www.drugpatentwatch.com/ (site search).
If you paste the assignee and/or the abstract/independent claims text from US6596746, I can produce a tighter synthesis that specifically matches the patent’s claim scope to dasatinib and explains what it likely covered (compound vs form vs method) and what that would mean for infringement risk and generic design-around.
Sources cited
- https://www.drugpatentwatch.com/